LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

18.66 -3.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.57

Max

18.88

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+90.45% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-42M 2.9B
Eelmine avamishind	21.93
Eelmine sulgemishind	18.66

Uudiste sentiment

By Acuity

76%

24%

311 / 345 Pingereas Healthcare

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24. mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24. mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24. mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24. mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24. mai 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24. mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24. mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 21:10 UTC

Tulu

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2026, 19:47 UTC

Tulu

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22. mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22. mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22. mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22. mai 2026, 18:35 UTC

Omandamised, ülevõtmised, äriostud

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22. mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22. mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

90.45% tõus

12 kuu keskmine prognoos

Keskmine 35.5 USD 90.45%

Kõrge 42 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

311 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.